Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary Fibrosis

Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary Fibrosis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary Fibrosis DJ Nagel, Takuma Okutani, Samia Lopa, TJ Mariani, PJ Sime, RM Kottmann, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7881084/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 11 You are reading this latest preprint version Abstract Background During the development of idiopathic pulmonary fibrosis (IPF), elastin is broken down and replaced with a stiffer substrate which interferes with normal breathing. This remodeling releases elastin degradation products (EDPs), or elastokines, which can then be measured. We examined the association between elastokine concentrations and disease severity to determine if EDP concentrations are associated with clinically relevant markers in IPF. Methods Concentrations of elastokines were measured via enzyme linked immunosorbent assay (ELISA). Samples were obtained from a single institution’s Interstitial Lung Disease (ILD) registry/biorepository (n = 81 with IPF and 24 healthy volunteers). We used linear and logistic regression modeling to assess the association between EDP concentrations at the time of diagnosis, lung function, and clinical outcomes. Results Patients with IPF were older, more likely to be male, had ever smoked, and had worse lung function compared to healthy volunteers (p value ≤ 0.02 for all parameters). Patients with IPF had higher concentrations of elasotkines (p < 0.001), and the highest elastokine concentrations were associated with reduced forced vital capacity (FVC, p = 0.026), and decreased three-year transplant-free survival (p = 0.0005). These findings suggest that elastokines are biomarkers of matrix turnover and are associated with relevant clinical outcomes in patients with IPF. Health sciences/Biomarkers Health sciences/Diseases Health sciences/Medical research pulmonary fibrosis elastokines elastin degradation products extracellular matrix remodeling and transplant-free survival Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Introduction Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause marked by progressive scarring of the lung occurring almost exclusively occurs in older adults. As the world’s population ages, its incidence and prevalence are on the rise( 1 ). The mechanisms by which IPF develops remain incompletely understood, but it is thought that an injury occurs to airway epithelial cells, leading to fibroblast activation/differentiation, and lung scarring. IPF carries a prognosis only slightly better than lung cancer( 2 ). Currently, there are two FDA-approved medications for the treatment of IPF: nintedanib (a triple kinase receptor inhibitor)( 3 ) and pirfenidone (a partial TGF-β antagnoist)( 4 ). While these medications decrease the rate of decline in FVC and reduce respiratory related hospitalizations, they do not reverse established fibrosis and are often not well-tolerated. The only cure for IPF is lung transplantation( 5 ). However, lung transplant survival rates are the lowest among solid organ transplants; the median survival rate after lung transplantation is 5.8 years( 6 ). Elastin is a hydrophobic polymer that provides tissue resilience, elasticity, and stability that is essential for proper lung function. During the development of IPF, pro-fibrotic cytokines, like transforming growth factor-beta (TGF-β), induce the activity of elastases and proteinases, which degrade mature elastin, and are increased in the lung tissue of patients with IPF( 7 ). Elastin is synthesized as tropoelastin by fibroblasts, smooth muscle cells, endothelial cells, and chondrocytes( 8 ) and is subsequently condensed to mature elastin in the extracellular space. Mature elastin is a polymer of cross-linked tropoelastin fibrils made of glycoproteins such as latent transforming growth factor β-binding proteins (LTBPs), fibrillin-1 and − 2, and microfibrillar-associated proteins (MFAPs)( 9 ). In healthy adult tissues, ultra-long proteins, like elastin, typically have a very low turnover rate (half-life of approximately 74 years)( 10 ). In contrast, most other proteins have half-lives of minutes, hours, or days( 11 ). However, when homeostatic conditions are altered by chronic illness, elastin turnover occurs much more rapidly. Adult tissues generally lack the ability to regenerate functional elastin fibers to counteract this increased turnover( 12 ), which can lead to irreversible changes in tissue structure and function. In addition, although elastin mRNA is stabilized by TGF-β( 13 ), over-expression of tropoelastin via transduction was not sufficient to induce elastic fiber formation( 14 ), indicating that degraded elastin is not easily replaced. When mature elastin is degraded, its amino acid constituents (isodesmosine and desmosine) and elastin sub-fragments (elastin degradation products or EDPs) (collectively known as elastokines) become liberated, where they can now be detected in body fluids, including urine, plasma, and bronchoalveolar lavage fluid( 15 ). Elastin-related pathology has significant prognostic information as several reports have shown an association between higher concentrations of circulating EDPs and increased mortality( 16 , 17 ). Indeed, increased elastin remodeling has been reported in diseases such as chronic obstructive pulmonary disease (COPD)( 18 , 19 ), pulmonary arterial hypertension( 20 ), abdominal aortic aneurysm, and rheumatoid arthritis( 21 ). It has also been shown that chronic diseases accelerate elastin turnover relative to age-matched controls( 22 ). Here we measured elastokine concentrations in patients with IPF compared to healthy controls and studied their association with relevant clinical outcomes. Results Baseline Demographics: Compared to healthy subjects, patients with IPF were older (71 vs 40 years of age, p <0.001)), more likely to be male (71.6% vs 37.5%, p =0.004), more likely to have ever smoked (69.1% vs 41.7%, p =0.021), and have a higher BMI (28.0 vs 24.3 kg/m 2 , p =0.003). Patients with IPF were more likely to be male (71.6% vs 28.4%, p =0.0001), Caucasian (97.5% vs 2.5%, p <0.0001), and have ever smoked (69.1% vs 30.9%, p =0.0006). Compared with healthy volunteers, patients with IPF had worse lung function (FVC 72% vs 99% predicted, p <0.001; DLCO 46% vs 82% predicted, p=0.08), a higher supplemental oxygen need (53.1% vs 0%), higher mortality (65.4% vs 0%) and more frequent transplant rates (12.35% vs 0%). Approximately 46% of patients with IPF were taking an anti-fibrotic medication. Association of Urinary Elastokines and IPF: To assess for differences in concentrations of desmosine and isodesmosine, we first analyzed urine samples from 81 patients with IPF and 24 healthy volunteers for desmosine concentrations. The average urinary desmosine level in patients with IPF (1.4 ng/mL) was significantly higher than in healthy volunteers was (0.321 ng/mL, Figure 1A, p<0.0001). We also assessed for differences in desmosine concentrations between people with COPD and IPF and found that those with IPF had significantly elevated elastokine concentrations (Supplemental Figure 1). While we didn’t have age-matched controls, the age between those with COPD (mean 64.9 years) and IPF (71.6 years) was similar. When age-adjusted desmosine concentrations were analyzed, there remained a statistically significant elevation among those with IPF (Supplemental Figure 2). These findings suggest that there are differences in desmosine concentrations that are diagnostic-specific among different chronic lung diseases and independent of age-related elastin changes. To assess for any potential difference in urinary elastokine concentrations, we then measured isodesmosine concentrations in a randomly selected subset of healthy individuals and those with IPF. Isodesmosine concentrations were also significantly elevated in patients with IPF (Figure 1B, p=0.002). This data demonstrates that people with IPF have higher urinary concentrations of both desmosine and isodesomine, suggesting they have higher rates of mature elastin fiber turnover. Assessment of Accuracy and Precision of Desmosine and Isodesmosine concentrations : It was previously unknown if urinary desmosine and isodesmosine concentrations are similarly elevated in patients with IPF. In theory, if one amino acid is more sensitive at detecting elastin turnover, then this could have potential clinical implications. Figure 1 demonstrates that both are significantly elevated, but we wanted to assess this at a more granular level. Therefore, we analyzed the correlation between these two amino acids between patients with IPF and healthy volunteers. As seen in Figure 2A, there was no significant difference when comparing urinary concentrations in either group. There was moderate correlation between urinary desmosine and isodesmosine in both cohorts (Figure 2B, pearson r coefficient of 0.5123). We next wanted to assess for differences in desmosine by specimen source and used biospecimens from matched patients to compare urinary and serum desmosine concentrations. As expected, concentrations in healthy volunteers were lower whether measured in serum or urine. While concentrations of both were higher in patients with IPF, there was no statistical difference between the two sources from the same donors (Figure 2C). We then compared for possible differences between desmosine and isodesmosine concentrations from the same source (urine) and found good agreement between both elastokines (Figure 2D). Taken together, these data indicate that urinary EDPs are a faithful reflection of serum EDP concentrations in healthy controls and patients with IPF. Association of Elastokine Elevation and Lung Function : The change in FVC over time has been used as a primary endpoint in clinical trials assessing the efficacy of medications for the treatment of IPF and has been correlated with mortality(44). Thus, we aimed to investigate the relationship between elastokine elevation and lung function. We found that higher EDP concentrations are associated with worse lung function, as measured by FVC (Figure 3A). While a similar correlation was observed with D L CO (Figure 3B), this did not reach statistical significance. Patients with higher concentrations of desmosine were more likely to be taking an anti-fibrotic medication (OR 2.057 [0.666-6.28] vs 0.4861 [0.1591 to 1.50], data not shown), but since some samples were collected prior to anti-fibrotic approval, we did not perform additional analysis and are unable to assess the effect of anti-fibrotic medications on elastokine concentrations over time. Transplant-Free Survival : We then examined the association between three-year transplant-free survival and urinary desmosine concentrations. To create the comparator groups, we divided elastokine concentrations in patients with IPF into tertiles and assessed time to event (lung transplant or death) for 36 months from the first sample donation. We found that elevated desmosine concentrations were significantly associated with a worse clinical outcome (Figure 4, HR of 15.04, p=0.0005). Elastokine Concentrations Associated with GAP Stage : The GAP (Gender, Age, and lung Physiology) staging system was initially created(42) and subsequently validated(43) to assess 1, 2, and 3-year mortality in patients with IPF. It uses a combination of gender, age, and two assessments of lung function (FVC and D L CO) to create a risk stratified stage. We assessed the association between GAP stage and elastokine elevation and found that the higher the elastokine level, the higher the GAP stage (Figure 5). This data further supports the association between elevated elastokines, IPF severity, and mortality. Discussion Here we present data demonstrating an association between elastin remodeling, lung function, and disease severity in IPF. This work supports previous data demonstrating increased elastokine concentrations in serum and bronchoalveolar lavage fluid in patients IPF(45, 46), and our measurements are consistent with the level reported by de Brouwer et. al.(45). Our work highlights the association between higher concentrations of elastokine and clinical prognosis. We observed a significant association between elastokine elevation and decreased FVC, the primary index used to evaluate therapeutic efficacy in IPF. We also observed a similar, though not statistically significant, association between elastokine concentration and reduced D L CO. These associations make intuitive sense as one would anticipate decreased lung function due to replacement of elastin, which confers tissue resilience, deformability, and elasticity by comparatively stiffer collagen and other ECM proteins. We previously demonstrated a decreased ratio of mature elastin relative to collage in patients with IPF(47), which supports the hypothesis that mature elastin is replaced by collagen in pulmonary fibrosis. Perhaps more importantly, in this study, we also observed an association between elastokine elevation and reduced three-year transplant-free survival. A correlation between elastokine concentration and GAP stage, a surrogate for mortality, further supported this finding. Our study also offers a potential practical advantage as the method of measurement we utilized is technically easier (ELISA assay), more widely available, and allows for high throughput processing compared to previously reported techniques that are more time, technical, and resource intensive(45, 46). We also demonstrate that desmosine and isodesmosine are readily detectable in both healthy volunteers and patients with IPF. In addition, there was good correlation between isodesmosine and desmosine concentrations regardless of the source (serum vs urine). As both were similarly elevated in patients in IPF, this suggests that elastin remodeling is the inciting event leading to release of these amino acids into the circulation. Finally, we also demonstrate that urinary and serum elastokine concentrations are consistently and similarly elevated in IPF. This adds to previous data measuring increased concentrations of circulating desmosine and isodesmosine in plasma(45) and bronchoalveolar lavage(46) samples in patients with IPF. We acknowledge several limitations of the current study. First, we used a single-center retrospective cohort that comprised mostly Caucasian males. Although the sex distribution may be expected, we recognize that underrepresented minority patients are not included in our cohort and that our findings may not be generalizable to more ethnically diverse populations. Additionally, as the guideline-based definition of IPF evolved over the course of enrollment, some time-dependent discrepancies may have arisen in the clinical diagnosis of IPF. Some of our patients had combined pulmonary fibrosis and emphysema and/or WHO Group 3 pulmonary hypertension (<10% of our cohort), and it is unclear whether these co-morbid conditions contributed to the elevations in elastokine concentrations. We were unable to analyze associations between longitudinal changes in lung function, transplant-free survival, and elastokines due to an insufficient sample size. We were also unable to assess for longitudinal changes in elastokine concentrations as a function of anti-fibrotic medication for similar reasons. As expected, there was a significant difference in age between healthy volunteers and patients with IPF; however, we did not have age-matched controls to differentiate between age-related and disease-related elastokine concentrations. Others have reported disease-specific increases above those expected from aging alone with respect to desmosine concentrations(22). Some degree of caution in interpreting our analyses is warranted due to the possibility of a Type I error given the relatively small sample size and the restricted geography from which biospecimens were obtained. However, our sample size was adequate based on our power calculation. In addition, our data is consistent with and builds upon previously published data. We plan to validate our findings with larger cohorts and, potentially, a prospective trial, ideally using comparative biomarker analysis. There have been many promising biomarkers and clinical therapies, but for a variety of reasons, most do not achieve FDA approval(23). Emerging evidence suggests that elastokines are not simply a biomarker of lung tissue remodeling but might also contribute to lung pathology. In addition to desmosine, isodesmosine, other proteins are members of the elastokine family including a-elastin, k-elastin, and a group of peptides with a conserved VGVAPG domain(24, 25). Elastokines have been shown to induce signal transduction and cell activation via several receptors including a v b 5 , galectrin-3, and integrins, but the majority of data suggests that the Elastin Receptor Complex (ERC) is probably the main receptor(25). This receptor is a heterotrimer composed of a peripheral subunit known as the Elastin Binding Protein, a protective protein/cathepsin A, and a membrane-associated protein called Neuraminidase-1. Elastokines have been shown to promote cell proliferation, invasion, survival, matrix metalloproteinase expression, angiogenesis, and fibroblast chemotaxis(26-32). Downstream signaling pathways of the ERC involve the MAP kinase family (ERK1/2) and pro-MMP-1 production(24). Preclinical administration of elastases is a well-established pre-clinical model of emphysema(33), however further research is needed into the mechanism(s) by which elastokines promote the development of emphysema and pulmonary fibrosis. The progressive nature of IPF combined with the increasing world-wide incidence and prevalence of this disease(48), especially in the context of having only two partially effective therapies(3, 4), represents an unmet medical need. There are several potential novel therapeutics on the horizon, but many promising therapies have fallen short of demonstrating durable efficacy(23, 49). We propose that any additional insight into potential biomarkers and/or mechanistic understanding of this devastating disease will only help move the field of fibrosis research forward. Conclusions Elevated concentrations of circulating elastokines, a marker of matrix turnover, are associated with worse lung function and reduced three-year transplant-free survival in patients with IPF. These results need to be confirmed with a validation cohort and studies examining the mechanism of EDP-induced fibrosis are currently underway. Study Design and Methods Study sample: The institution’s ILD registry/biorepository was created with institutional approval in 2008 (STUDY00000503) and has been reviewed annually since its inception. The diagnosis of IPF was designated either according to the current professional guidelines or through multi-disciplinary discussion(34-38). Patients who expressed an interest in participating were consented at any time in the process of their disease and could donate biospecimens serially. For this analysis we used the first donation that was either the closest to when consent was obtained or when the diagnosis was first documented (often occurring at the same visit). Clinical outcomes (lung transplant or death) were then observed for a period of three years after initial sample collection. If the patient survived or did not receive a transplant during those three years, lung transplant-free survival was documented. Urinary and circulating elastokine measurement: The concentration of amino acids desmosine and isodesmosine was measured primarily in urine and serum via a commercially available enzyme-linked immunosorbent assay (ELISA) kit (mybiosource.com, Catalog # MBS702024 and MBS702214, respectively). Urine samples were available for the entire cohort (n=81 patients with IPF, n=24 healthy controls), and serum samples were available from a subset (n=24 patients with IPF, n=8 from healthy controls). We chose to use urine as the primary source because it is the least invasive and most widely available biospecimen in the repository. Samples were stored at -80° C until they were thawed for use. Duplicates for standards and each patient sample were used, and elastokine measurement was performed according to manufacturer instructions using replicates for each donor. The product literature states that for both assays, the intra-assay coefficient of variation is < 8% and the inter-assay precision has a coefficient of variation of < 10%. Quatitative measurements were then obtained based on absorption at 450 nm with an iMark microplate reader (Bio-Rad). Results were then analyzed and graphed using GraphPad Prism (v10) or SAS (v9.4). Physiologic Assessments: Spirometry (forced vital capacity, FVC) and diffusing capacity for carbon monoxide (D L CO) were performed as part of standard clinical care, in accordance with current professional guidelines(39-41). Patients typically underwent lung function testing on the day of their clinical appointment; however, consent, enrollment, and sample donation may have occurred on a different day from their clinic appointment. In these cases, spirometry values that were obtained closest to the enrollment date were considered the baseline values for each participant. Adjudication of Death and Lung Transplantation: Death and lung transplantation status were adjudicated by the study personnel (investigators and study coordination staff). Time to censored event occurred for a period of 3 years following the initial date of sample donation. Statistical Analysis: Based on a prior study demonstrating the effect size of fold change in EDP concentration to be 10 units per 1 standard deviation(8) and confirmation of this effect size from our preliminary data, a patient sample size of 63 was deemed necessary to detect the same effect size at 80% power and a two-sided 0.05 significance level. Socio-demographic and clinical variables investigated include FVC, D L CO, smoking status, gender, ethnicity, race, age, presence of hypoxemia, and anti-fibrotic medication use. Linear and logistic regression modeling was utilized to determine associations between changes in urine EDP concentrations and lung function. Secondary analyses included the effect of anti-fibrotic medications on EDP concentration and assessment of associations between EDP concentrations at the time of diagnosis and clinical outcomes (time to respiratory-related hospitalization, transplant, or death). For the latter, we used time to event analysis to assess 3-year transplant-free survival. To create the comparator groups, we divided elastokine concentrations into tertiles. The GAP (Gender, Age, and lung Physiology) staging system was initially created(42) and subsequently validated(43) to assess 1, 2, and 3-year mortality in patients with IPF. We assessed EDP concentration as a function of GAP stage to provide additional support for the prognostic implications of elevated EDP concentrations. It is unknown if there is a relative difference in amino acid release between desmosine and isodesomine under conditions of elastinolysis. To assess the precision of urinary isodesmosine versus desmosine to detect a change in EDP concentrations, we selected a random sub-population and performed a correlation analysis based on urinary ELISA concentrations. It is also unclear if there are relative differences in EDP concentrations based on specimen source. To assess the accuracy of desmosine measurement between urinary and serum sources we used Bland-Altman analysis, using a different set of randomly selected patients. All statistical analysis was performed either with GraphPad Prism (v10, DJN) or SAS (v9.4, SL) software packages. Statistical significance was considered when p < 0.05. Most figures were created using a combination of the above programs and BioRender (biorender.com) Declarations Acknowledgements: The authors would like to thank the current and former research coordinators and patients who donated specimens. We would also like to thank Drs. Patricia Rivera and Steve Georas for manuscript feedback. Authors’ contributions: DJN, RMK, and DH conceptualized the study. DJN was responsible for experimental design, data analysis, figure creation, and manuscript writing. TO and DJN performed ELISA analyses and DJN compiled results for statistical analysis. TJM, PJS, RMK, and DH provided project guidance, critical analysis of experimental results, and feedback on manuscript writing. Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request. All patient-related information has been de-identified and each participant was assigned a unique identification upon consent. Competing interests: The authors do not have any competing interests to declare. Ethics Approval: This study was performed in accordance with the Declaration of Helsinki. This human study was approved by University of Rochester Research Subjects Review Board - approval: STUDY00000503. All adult participants provided written informed consent to participate in this study. Funding: DJN was supported by the URMC Multidisciplinary Training Program in Pulmonary Research (T32-HL066988, NHLBI), the URMC Department of Medicine Faculty Pilot Project Award, the NIH Loan Repayment Program (PTDX4691, NHLBI), and the CHEST Research Grant in Pulmonary Fibrosis (2023-2024). Statistical analysis was performed by SL and supported in part by the Department of Medicine Biostatistical Shared Resource and the University of Rochester School of Medicine and Dentistry. References Kaul B, Lee JS, Zhang N, Vittinghoff E, Sarmiento K, Collard HR, Whooley MA. Epidemiology of Idiopathic Pulmonary Fibrosis among U.S. Veterans, 2010-2019. Ann Am Thorac Soc 2022; 19: 196-203. Ley B, Collard HR, King TE, Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England journal of medicine 2014; 370: 2071-2082. King TE, Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England journal of medicine 2014; 370: 2083-2092. Valapour M, Lehr CJ, Skeans MA, Smith JM, Carrico R, Uccellini K, Lehman R, Robinson A, Israni AK, Snyder JJ, Kasiske BL. OPTN/SRTR 2016 Annual Data Report: Lung. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2018; 18 Suppl 1: 363-433. Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis 2017; 9: 2684-2691. Kristensen JH, Karsdal MA, Sand JM, Willumsen N, Diefenbach C, Svensson B, Hagglund P, Oersnes-Leeming DJ. Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling. BMC pulmonary medicine 2015; 15: 53. Starcher BC. Elastin and the lung. Thorax 1986; 41: 577-585. Mithieux SM, Weiss AS. Tandem integration of multiple ILV5 copies and elevated transcription in polyploid yeast. Yeast 1995; 11: 311-316. Shapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J Clin Invest 1991; 87: 1828-1834. Boisvert F-M, Ahmad Y, Gierliński M, Charrière F, Lamont D, Scott M, Barton G, Lamond AI. A quantitative spatial proteomics analysis of proteome turnover in human cells. Molecular & Cellular Proteomics 2012; 11. Cocciolone AJ, Hawes JZ, Staiculescu MC, Johnson EO, Murshed M, Wagenseil JE. Elastin, arterial mechanics, and cardiovascular disease. Am J Physiol Heart Circ Physiol 2018; 315: H189-h205. Zhang MC, Giro M, Quaglino D, Jr., Davidson JM. Transforming growth factor-beta reverses a posttranscriptional defect in elastin synthesis in a cutis laxa skin fibroblast strain. J Clin Invest 1995; 95: 986-994. Katsuta Y, Ogura Y, Iriyama S, Goetinck PF, Klement JF, Uitto J, Amano S. Fibulin-5 accelerates elastic fibre assembly in human skin fibroblasts. Exp Dermatol 2008; 17: 837-842. Huang JT, Bolton CE, Miller BE, Tal-Singer R, Rabinovich RA, Palmer CN, Thomson NC, MacNee W. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. The European respiratory journal 2016; 48: 1215-1218. Huang JT, Kuzmanova E, Dicker AJ, Keir HR, Finch S, Aliberti S, Fardon TC, Chalmers JD. Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. Am J Respir Crit Care Med 2020; 202: 897-899. Rabinovich RA, Miller BE, Wrobel K, Ranjit K, Williams MC, Drost E, Edwards LD, Lomas DA, Rennard SI, Agustí A, Tal-Singer R, Vestbo J, Wouters EF, John M, van Beek EJ, Murchison JT, Bolton CE, MacNee W, Huang JT. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. The European respiratory journal 2016; 47: 1365-1373. Fregonese L, Ferrari F, Fumagalli M, Luisetti M, Stolk J, Iadarola P. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antritrypsin deficiency-related COPD. Copd 2011; 8: 329-333. Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 637-641. Kim YM, Haghighat L, Spiekerkoetter E, Sawada H, Alvira CM, Wang L, Acharya S, Rodriguez-Colon G, Orton A, Zhao M, Rabinovitch M. Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. The American journal of pathology 2011; 179: 1560-1572. Shek N, Choy AM, Lang CC, Miller BE, Tal-Singer R, Bolton CE, Thomson NC, Chalmers JD, Bown MJ, Newby DE, Khan F, Huang JTJ. Accelerated elastin degradation by age-disease interaction: a common feature in age-related diseases. NPJ Aging 2024; 10: 15. Huang JTJ, Bolton CE, Miller BE, Tal-Singer R, Rabinovich RA, Palmer CNA, Thomson NC, MacNee W. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. European Respiratory Journal 2016; 48: 1215-1218. Rackow AR, Nagel DJ, McCarthy C, Judge J, Lacy S, Freeberg MAT, Thatcher TH, Kottmann RM, Sime PJ. The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops. The European respiratory journal 2020; 56. Duca L, Blanchevoye C, Cantarelli B, Ghoneim C, Dedieu S, Delacoux F, Hornebeck W, Hinek A, Martiny L, Debelle L. The elastin receptor complex transduces signals through the catalytic activity of its Neu-1 subunit. The Journal of biological chemistry 2007; 282: 12484-12491. Scandolera A, Odoul L, Salesse S, Guillot A, Blaise S, Kawecki C, Maurice P, El Btaouri H, Romier-Crouzet B, Martiny L, Debelle L, Duca L. The Elastin Receptor Complex: A Unique Matricellular Receptor with High Anti-tumoral Potential. Front Pharmacol 2016; 7: 32. Brassart B, Randoux A, Hornebeck W, Emonard H. Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. Clinical & experimental metastasis 1998; 16: 489-500. Coquerel B, Poyer F, Torossian F, Dulong V, Bellon G, Dubus I, Reber A, Vannier JP. Elastin-derived peptides: matrikines critical for glioblastoma cell aggressiveness in a 3-D system. Glia 2009; 57: 1716-1726. Donet M, Brassart-Pasco S, Salesse S, Maquart FX, Brassart B. Elastin peptides regulate HT-1080 fibrosarcoma cell migration and invasion through an Hsp90-dependent mechanism. Br J Cancer 2014; 111: 139-148. Duca L, Lambert E, Debret R, Rothhut B, Blanchevoye C, Delacoux F, Hornebeck W, Martiny L, Debelle L. Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts. Molecular pharmacology 2005; 67: 1315-1324. Ntayi C, Labrousse AL, Debret R, Birembaut P, Bellon G, Antonicelli F, Hornebeck W, Bernard P. Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma cell invasion through elastin-binding protein. J Invest Dermatol 2004; 122: 256-265. Senior RM, Griffin GL, Mecham RP, Wrenn DS, Prasad KU, Urry DW. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. The Journal of cell biology 1984; 99: 870-874. Toupance S, Brassart B, Rabenoelina F, Ghoneim C, Vallar L, Polette M, Debelle L, Birembaut P. Elastin-derived peptides increase invasive capacities of lung cancer cells by post-transcriptional regulation of MMP-2 and uPA. Clinical & experimental metastasis 2012; 29: 511-522. Kuhn C, Senior RM. The role of elastases in the development of emphysema. Lung 1978; 155: 185-197. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664. Erratum: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: 644. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Jr., Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198: e44-e68. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205: e18-e47. Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, MacIntyre NR, Thompson BR, Wanger J. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. The European respiratory journal 2017; 49. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019; 200: e70-e88. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. The European respiratory journal 2005; 26: 319-338. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Jr., Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691. Kim ES, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM. Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. Chest 2015; 147: 430-437. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. The New England journal of medicine 2015; 372: 1189-1191. de Brouwer B, Drent M, van den Ouweland JMW, Wijnen PA, van Moorsel CHM, Bekers O, Grutters JC, White ES, Janssen R. Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis. Respiratory research 2018; 19: 45. Sato T, Kajikuri T, Saito Y, Chikuma M, Nagai S. Determination of desmosine in bronchoalveolar lavage fluids by time-resolved fluoroimmunoassay. Clinica chimica acta; international journal of clinical chemistry 2008; 387: 113-119. Kottmann RM, Sharp J, Owens K, Salzman P, Xiao GQ, Phipps RP, Sime PJ, Brown EB, Perry SW. Second harmonic generation microscopy reveals altered collagen microstructure in usual interstitial pneumonia versus healthy lung. Respiratory research 2015; 16: 61. King TE, Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet (London, England) 2011; 378: 1949-1961. Fuster-Martínez I, Calatayud S. The current landscape of antifibrotic therapy across different organs: A systematic approach. Pharmacol Res 2024; 205: 107245. Table Table 1: Baseline patient characteristics. Variable Healthy IPF p-value Age (Yrs) N=24 N=81 <0.001 Median (IQR) 40.0 (29.0 : 63.5) 71.0 (66.0 : 79.0) Gender 0.006 Male 9 (37.5%) 58 (71.6%) Female 15 (62.5%) 23 (28.4%) Race 0.21 White 22 (91.7%) 79 (97.5%) Non-white 2 (8.3%) 2 (2.5%) Ever smoker 0.021 No 14 (58.3%) 25 (30.9%) Yes 10 (41.7%) 56 (69.1%) BMI 0.005 Median (IQR) 24.4 (23.3 : 28.0) 28.0 (25.7 : 32.4) FVC (% predicted) <0.001 Median (IQR) 99.0 (91.0 : 108.0) 72.0 (64.0 : 84.0) D L CO (% predicted) N=2 N=80 <0.001 Median (IQR) 96.5 (84.0 : 109.0) 46.0 (37.0 : 54.5) Desmosine (ng/mL) <0.001 Median (IQR) 0.3 (0.2 : 0.4) 1.4 (0.8 : 2.5) Oxygen needs <0.001 No 23 (100.0%) 38 (46.9%) Yes 0 (0.0%) 43 (53.1%) Anti-fibrotic use No 0 (0.0%) 44 (54.32%) Yes 0 (0.0%) 37 (45.68%) Death No 0 (0.0%) 28 (34.6%) Yes 0 (0.0%) 53 (65.4%) Transplant No 0 (0.0%) 72 (87.7%) Yes 0 (0.0%) 10 (12.3%) Data comparing healthy volunteers and patients with IPF are presented as No. (%) with median and interquartile ranges for relevant parameters. Among those with IPF, patients were more likely to be male (71.6% vs 28.4%, p = 0.0001), Caucasian (97.5% vs 2.5%, p <0.0001), and have ever smoked (69.1% vs 30.9%, p = 0.0006). Additional Declarations No competing interests reported. Supplementary Files SupplementalFigures.pdf Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 09 Feb, 2026 Reviews received at journal 19 Jan, 2026 Reviewers agreed at journal 07 Jan, 2026 Reviewers agreed at journal 02 Jan, 2026 Reviews received at journal 25 Dec, 2025 Reviewers agreed at journal 25 Dec, 2025 Reviewers invited by journal 25 Dec, 2025 Editor invited by journal 30 Oct, 2025 Editor assigned by journal 17 Oct, 2025 Submission checks completed at journal 17 Oct, 2025 First submitted to journal 16 Oct, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7881084","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":566242876,"identity":"86887ec6-5729-4164-90f7-ed9d49bc80dc","order_by":0,"name":"DJ Nagel","email":"data:image/png;base64,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","orcid":"","institution":"University of Rochester Medical Center","correspondingAuthor":true,"prefix":"","firstName":"DJ","middleName":"","lastName":"Nagel","suffix":""},{"id":566242877,"identity":"f2a8a8a2-4434-4806-89df-eb3db0009333","order_by":1,"name":"Takuma Okutani","email":"","orcid":"","institution":"University of Rochester Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Takuma","middleName":"","lastName":"Okutani","suffix":""},{"id":566242878,"identity":"e5d13e35-a5b9-4e73-8323-724040a0ae12","order_by":2,"name":"Samia Lopa","email":"","orcid":"","institution":"University of Rochester Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Samia","middleName":"","lastName":"Lopa","suffix":""},{"id":566242879,"identity":"d8d268e8-e96f-4a1a-a0d0-9355471f5b10","order_by":3,"name":"TJ Mariani","email":"","orcid":"","institution":"University of Rochester Medical Center","correspondingAuthor":false,"prefix":"","firstName":"TJ","middleName":"","lastName":"Mariani","suffix":""},{"id":566242880,"identity":"51a96b8d-4d8a-4032-869f-8aff52fe8302","order_by":4,"name":"PJ Sime","email":"","orcid":"","institution":"Virginia Commonwealth University","correspondingAuthor":false,"prefix":"","firstName":"PJ","middleName":"","lastName":"Sime","suffix":""},{"id":566242882,"identity":"1ca46dfc-de07-4fdd-b6d9-27a7c321def2","order_by":5,"name":"RM Kottmann","email":"","orcid":"","institution":"University of Rochester Medical Center","correspondingAuthor":false,"prefix":"","firstName":"RM","middleName":"","lastName":"Kottmann","suffix":""},{"id":566242884,"identity":"530cf6a4-394f-4026-b2aa-48526de2306d","order_by":6,"name":"Denise Hocking","email":"","orcid":"","institution":"University of Rochester Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Denise","middleName":"","lastName":"Hocking","suffix":""}],"badges":[],"createdAt":"2025-10-16 22:08:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7881084/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7881084/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":99318837,"identity":"878d5e1b-f653-4ff6-a319-289596162b12","added_by":"auto","created_at":"2025-12-31 16:35:18","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":53116,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/5b9bba55feb303a4e615f3a9.docx"},{"id":99317682,"identity":"f7a31256-7e06-4f81-933a-35f829d682f0","added_by":"auto","created_at":"2025-12-31 16:30:35","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":124274,"visible":true,"origin":"","legend":"","description":"","filename":"EDPsinIPFSR.docx","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/01fa1f65015f8e4ec14b3789.docx"},{"id":99318885,"identity":"22c9fbca-0ee8-47eb-830b-c69f6041d63e","added_by":"auto","created_at":"2025-12-31 16:35:36","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":17019,"visible":true,"origin":"","legend":"","description":"","filename":"Table1EDP.docx","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/9cde1c3732f68d00d2ce1d0e.docx"},{"id":99317111,"identity":"728193a1-bd32-4610-8135-3f42a49d1d26","added_by":"auto","created_at":"2025-12-31 16:29:39","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":275286,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.docx","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/a0a31da7e276a5fb62b67890.docx"},{"id":99223397,"identity":"0b8f27be-ce54-40d5-b1fc-438deb6ea7a1","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"docx","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":70704,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.docx","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/3632d1817cceb702e70b65eb.docx"},{"id":99320182,"identity":"c50c5a34-b8cd-402f-81aa-2e1fd2276040","added_by":"auto","created_at":"2025-12-31 16:38:22","extension":"docx","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":55225,"visible":true,"origin":"","legend":"","description":"","filename":"Figure4.docx","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/8351c32734c3e2252135c82b.docx"},{"id":99223407,"identity":"9e4f36e8-e45a-446c-8f3c-0707ef662e73","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"docx","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":62744,"visible":true,"origin":"","legend":"","description":"","filename":"Figure5.docx","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/ced301e4301e7408c3442bca.docx"},{"id":99319007,"identity":"74d0ce47-d9f2-44d9-9072-0984076a023c","added_by":"auto","created_at":"2025-12-31 16:35:59","extension":"json","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":8584,"visible":true,"origin":"","legend":"","description":"","filename":"faadf3b37d794ffeb6697c420713e8b5.json","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/f71e6b68cd45f4dde756ffb7.json"},{"id":99223399,"identity":"718ad8b5-b01d-4cab-b083-c7812fe636f0","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"pdf","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":260115,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalFigures.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/f014be3d2a73d8e514df7e1a.pdf"},{"id":99223408,"identity":"7a0bc24f-c028-40d6-844a-3b8f4afa654d","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"xml","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":124123,"visible":true,"origin":"","legend":"","description":"","filename":"faadf3b37d794ffeb6697c420713e8b51enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/f8ebed321be80755a491ca24.xml"},{"id":99318332,"identity":"ac095b35-850a-48f7-a92f-4b1806544672","added_by":"auto","created_at":"2025-12-31 16:32:45","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":36340,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/23316f7781ff9b2faf1a3592.png"},{"id":99317239,"identity":"1fa93a5d-76ec-48f2-8637-6fb625879284","added_by":"auto","created_at":"2025-12-31 16:29:49","extension":"jpeg","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":205102,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/978d3ebb5e61b8a430bb0d9c.jpeg"},{"id":99223400,"identity":"e77e40ee-4af2-4499-a5e7-a9fdae281f0d","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"jpeg","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":148388,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/5209b45826758eeee06ed775.jpeg"},{"id":99320197,"identity":"2f0ec3f8-a147-47f6-aa8f-0a7f1e45c36f","added_by":"auto","created_at":"2025-12-31 16:38:23","extension":"jpeg","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":125150,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage4.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/29b8e022986ef931023a1f39.jpeg"},{"id":99318825,"identity":"f7a3ee6d-4e3d-4bea-8809-5fdbf567beda","added_by":"auto","created_at":"2025-12-31 16:35:04","extension":"jpeg","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":116624,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage5.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/78b4fc29fc212463d266adf9.jpeg"},{"id":99223406,"identity":"295da7f7-620c-4e60-8156-1ece8c19c0cd","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"png","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9086,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/ef7b5f1ed379af721a9999c5.png"},{"id":99223411,"identity":"62ef7e5d-7aac-4b03-ae55-1cbb19bf0946","added_by":"auto","created_at":"2025-12-30 10:00:11","extension":"png","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":57005,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/ad8de599d80ba3aea82d0261.png"},{"id":99223409,"identity":"fa204cbf-b51c-4b00-bf9e-a50f0ce018a6","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"png","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":105471,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/56d661607015f0e14d16eab0.png"},{"id":99223395,"identity":"a57929d6-afd5-4fd2-b8ba-8696f65fbf3d","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"png","order_by":18,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":24409,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/8109bc005032c2472eea1d3b.png"},{"id":99223396,"identity":"d79463d0-37a8-4270-a8b7-dcc59a561ed4","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"png","order_by":19,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":83393,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/edb8799c844ec273b250281f.png"},{"id":99223403,"identity":"e647b419-fb14-4493-8160-9fa5ee511def","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"xml","order_by":20,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":121491,"visible":true,"origin":"","legend":"","description":"","filename":"faadf3b37d794ffeb6697c420713e8b51structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/2701e9304665623748eb2c90.xml"},{"id":99223402,"identity":"76be84f9-778e-4d45-9d4e-8583fe03f557","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"html","order_by":21,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":138346,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/8902c9a1dc74b13604fabcd7.html"},{"id":99223383,"identity":"1843722d-1f36-4224-baf1-16204acffa36","added_by":"auto","created_at":"2025-12-30 10:00:08","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":125546,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eElastokine concentrations are elevated in \u003c/em\u003eIPF. Urinary concentrations of desmosine and isodesmosine were compared among healthy volunteers and patients with IPF. Both desmosine (A) and isodesmosine (B) concentrations are significantly higher in patients with IPF. Desmosine p (****) \u0026lt; 0.0001 and isodesmosine p (**) 0.002.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/fb6a528d92bd68fb3cf2ab39.png"},{"id":99319009,"identity":"5f0b40e5-7bfc-4694-a3d1-c3510ae81a21","added_by":"auto","created_at":"2025-12-31 16:35:59","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":180577,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eElastokine concentrations are similar regardless of source\u003c/em\u003e. Urinary concentrations of isodesmosine and desmosine were compared (A and B). The relative concentrations of desmosine were compared by source as well (C and D). There was no significant difference between isodesmosine and desmosine measurements (A) and pearson r coefficient was 0.5123 [0.193 – 0.7335] (B). There were no stastical differences in desmosine concentrations when measured from serum or urine (C). Bland-Altman analysis (D) revealed a bias of -0.049 (Limits of Agreement: -2.117 – 2.019).\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/e1cba5d2582b32d2d02554ca.png"},{"id":99320224,"identity":"40a3f9bd-ec20-4ef2-a4c8-ed9138cdec19","added_by":"auto","created_at":"2025-12-31 16:38:24","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":151670,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eElastokine concentrations are inversely associated with Forced Vital Capacity\u003c/em\u003e. Higher concentrations of desmosine are associated with a reduced forced vital capacity (FVC, A). However, a significant correlation was not observed with diffusing capacity (B). Correlation analysis for FVC (A) revealed a r coefficient of -0.254, p = 0.026. For diffusing capacity (B), the r coefficient was -0.206, p = 0.074.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/5aac17c611771d22cb685145.png"},{"id":99318291,"identity":"00c8927d-fc55-4a2d-bac6-5c1592143bf8","added_by":"auto","created_at":"2025-12-31 16:32:34","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":96328,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eThree-year transplant-free survival\u003c/em\u003e. Higher concentrations of desmosine are associated with a worse transplant-free survival within 3 years of initial sample donation. Desmosin concentrations of patients with IPF were divided into tertiles and then Kaplan-Meier analysis was performed. HR (Mantel-Cox) 15.04, p = 0.0005.\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/217d9af6b8f392d0569c2ed0.png"},{"id":99223401,"identity":"fb025f9d-c6c5-4c75-bfb5-92ae143b0531","added_by":"auto","created_at":"2025-12-30 10:00:10","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":115224,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eEDP concentrations and the association with GAP stage\u003c/em\u003e. Higher concentrations of desmosine are associated with a worse GAP stage. Comparison of GAP 2 to 3 p = 0.0018 and GAP 1 to 3 p \u0026lt; 0.0001.\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/f8260591c1224b66d7251912.png"},{"id":99324297,"identity":"f7c451c6-0873-49cf-8b26-b8b63e88132c","added_by":"auto","created_at":"2025-12-31 16:47:13","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1373502,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/d5bca08d-1370-4f55-a42a-064497321367.pdf"},{"id":99318271,"identity":"32ae8b42-2321-4453-a634-694266cc1278","added_by":"auto","created_at":"2025-12-31 16:32:31","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":260115,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalFigures.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7881084/v1/e2040e3e5cc795a865635f49.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary Fibrosis","fulltext":[{"header":"Introduction","content":"\u003cp\u003eIdiopathic pulmonary fibrosis (IPF) is a disease of unknown cause marked by progressive scarring of the lung occurring almost exclusively occurs in older adults. As the world\u0026rsquo;s population ages, its incidence and prevalence are on the rise(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). The mechanisms by which IPF develops remain incompletely understood, but it is thought that an injury occurs to airway epithelial cells, leading to fibroblast activation/differentiation, and lung scarring. IPF carries a prognosis only slightly better than lung cancer(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). Currently, there are two FDA-approved medications for the treatment of IPF: nintedanib (a triple kinase receptor inhibitor)(\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e) and pirfenidone (a partial TGF-β antagnoist)(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e). While these medications decrease the rate of decline in FVC and reduce respiratory related hospitalizations, they do not reverse established fibrosis and are often not well-tolerated. The only cure for IPF is lung transplantation(\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). However, lung transplant survival rates are the lowest among solid organ transplants; the median survival rate after lung transplantation is 5.8 years(\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eElastin is a hydrophobic polymer that provides tissue resilience, elasticity, and stability that is essential for proper lung function. During the development of IPF, pro-fibrotic cytokines, like transforming growth factor-beta (TGF-β), induce the activity of elastases and proteinases, which degrade mature elastin, and are increased in the lung tissue of patients with IPF(\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). Elastin is synthesized as tropoelastin by fibroblasts, smooth muscle cells, endothelial cells, and chondrocytes(\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e) and is subsequently condensed to mature elastin in the extracellular space. Mature elastin is a polymer of cross-linked tropoelastin fibrils made of glycoproteins such as latent transforming growth factor β-binding proteins (LTBPs), fibrillin-1 and \u0026minus;\u0026thinsp;2, and microfibrillar-associated proteins (MFAPs)(\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). In healthy adult tissues, ultra-long proteins, like elastin, typically have a very low turnover rate (half-life of approximately 74 years)(\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). In contrast, most other proteins have half-lives of minutes, hours, or days(\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). However, when homeostatic conditions are altered by chronic illness, elastin turnover occurs much more rapidly. Adult tissues generally lack the ability to regenerate functional elastin fibers to counteract this increased turnover(\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e), which can lead to irreversible changes in tissue structure and function. In addition, although elastin mRNA is stabilized by TGF-β(\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e), over-expression of tropoelastin via transduction was not sufficient to induce elastic fiber formation(\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e), indicating that degraded elastin is not easily replaced.\u003c/p\u003e \u003cp\u003eWhen mature elastin is degraded, its amino acid constituents (isodesmosine and desmosine) and elastin sub-fragments (elastin degradation products or EDPs) (collectively known as elastokines) become liberated, where they can now be detected in body fluids, including urine, plasma, and bronchoalveolar lavage fluid(\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e). Elastin-related pathology has significant prognostic information as several reports have shown an association between higher concentrations of circulating EDPs and increased mortality(\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). Indeed, increased elastin remodeling has been reported in diseases such as chronic obstructive pulmonary disease (COPD)(\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e), pulmonary arterial hypertension(\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e), abdominal aortic aneurysm, and rheumatoid arthritis(\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e). It has also been shown that chronic diseases accelerate elastin turnover relative to age-matched controls(\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eHere we measured elastokine concentrations in patients with IPF compared to healthy controls and studied their association with relevant clinical outcomes.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eBaseline Demographics:\u0026nbsp;\u003c/strong\u003e\u003c/em\u003eCompared to healthy subjects, patients with IPF were older (71 vs 40 years of age, p \u0026lt;0.001)), more likely to be male (71.6% vs 37.5%, p =0.004), more likely to have ever smoked (69.1% vs 41.7%, p =0.021), and have a higher BMI (28.0 vs 24.3 kg/m\u003csup\u003e2\u003c/sup\u003e, p =0.003). Patients with IPF were more likely to be male (71.6% vs 28.4%, p =0.0001), Caucasian (97.5% vs 2.5%, p \u0026lt;0.0001), and have ever smoked (69.1% vs 30.9%, p =0.0006). Compared with healthy volunteers, patients with IPF had worse lung function (FVC 72% vs 99% predicted, p \u0026lt;0.001; DLCO 46% vs 82% predicted, p=0.08), a higher supplemental oxygen need (53.1% vs 0%), higher mortality (65.4% vs 0%) and more frequent transplant rates (12.35% vs 0%). \u0026nbsp;Approximately 46% of patients with IPF were taking an anti-fibrotic medication.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eAssociation of Urinary Elastokines and IPF:\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eTo assess for differences in concentrations of desmosine and isodesmosine, we first analyzed urine samples from 81 patients with IPF and 24 healthy volunteers for desmosine concentrations. The average urinary desmosine level in patients with IPF (1.4 ng/mL) was significantly higher than in healthy volunteers was (0.321 ng/mL, Figure 1A, p\u0026lt;0.0001). We also assessed for differences in desmosine concentrations between people with COPD and IPF and found that those with IPF had significantly elevated elastokine concentrations (Supplemental Figure 1). While we didn\u0026rsquo;t have age-matched controls, the age between those with COPD (mean 64.9 years) and IPF (71.6 years) was similar. When age-adjusted desmosine concentrations were analyzed, there remained a statistically significant elevation among those with IPF (Supplemental Figure 2). These findings suggest that there are differences in desmosine concentrations that are diagnostic-specific among different chronic lung diseases and independent of age-related elastin changes.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo assess for any potential difference in urinary elastokine concentrations, we then measured isodesmosine concentrations in a randomly selected subset of healthy individuals and those with IPF. Isodesmosine concentrations were also significantly elevated in patients with IPF (Figure 1B, p=0.002). This data demonstrates that people with IPF have higher urinary concentrations of both desmosine and isodesomine, suggesting they have higher rates of mature elastin fiber turnover. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eAssessment of Accuracy and Precision of Desmosine and Isodesmosine concentrations\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e:\u0026nbsp;\u003c/strong\u003eIt was previously unknown if urinary desmosine and isodesmosine concentrations are similarly elevated in patients with IPF. In theory, if one amino acid is more sensitive at detecting elastin turnover, then this could have potential clinical implications. Figure 1 demonstrates that both are significantly elevated, but we wanted to assess this at a more granular level. Therefore, we analyzed the correlation between these two amino acids between patients with IPF and healthy volunteers. As seen in Figure 2A, there was no significant difference when comparing urinary concentrations in either group. There was moderate correlation between urinary desmosine and isodesmosine in both cohorts (Figure 2B, pearson r coefficient of 0.5123). \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe next wanted to assess for differences in desmosine by specimen source and used biospecimens from matched patients to compare urinary and serum desmosine concentrations. As expected, concentrations in healthy volunteers were lower whether measured in serum or urine. While concentrations of both were higher in patients with IPF, there was no statistical difference between the two sources from the same donors (Figure 2C). We then compared for possible differences between desmosine and isodesmosine concentrations from the same source (urine) and found good agreement between both elastokines (Figure 2D). Taken together, these data indicate that urinary EDPs are a faithful reflection of serum EDP concentrations in healthy controls and patients with IPF.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eAssociation of Elastokine Elevation and Lung Function\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e:\u0026nbsp;\u003c/strong\u003eThe change in FVC over time has been used as a primary endpoint in clinical trials assessing the efficacy of medications for the treatment of IPF and has been correlated with mortality(44). Thus, we aimed to investigate the relationship between elastokine elevation and lung function. We found that higher EDP concentrations are associated with worse lung function, as measured by FVC (Figure 3A). While a similar correlation was observed with D\u003csub\u003eL\u003c/sub\u003eCO (Figure 3B), this did not reach statistical significance. Patients with higher concentrations of desmosine were more likely to be taking an anti-fibrotic medication (OR 2.057 [0.666-6.28] vs 0.4861 [0.1591 to 1.50], data not shown), but since some samples were collected prior to anti-fibrotic approval, we did not perform additional analysis and are unable to assess the effect of anti-fibrotic medications on elastokine concentrations over time.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eTransplant-Free Survival\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e:\u0026nbsp;\u003c/strong\u003eWe then examined the association between three-year transplant-free survival and urinary desmosine concentrations. To create the comparator groups, we divided elastokine concentrations in patients with IPF into tertiles and assessed time to event (lung transplant or death) for 36 months from the first sample donation. We found that elevated desmosine concentrations were significantly associated with a worse clinical outcome (Figure 4, HR of 15.04, p=0.0005).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eElastokine Concentrations Associated with GAP Stage\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e:\u003c/strong\u003e The GAP (Gender, Age, and lung Physiology) staging system was initially created(42) and subsequently validated(43) to assess 1, 2, and 3-year mortality in patients with IPF. It uses a combination of gender, age, and two assessments of lung function (FVC and D\u003csub\u003eL\u003c/sub\u003eCO) to create a risk stratified stage. We assessed the association between GAP stage and elastokine elevation and found that the higher the elastokine level, the higher the GAP stage (Figure 5). This data further supports the association between elevated elastokines, IPF severity, and mortality. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eHere we present data demonstrating an association between elastin remodeling, lung function, and disease severity in IPF. This work supports previous data demonstrating increased elastokine concentrations in serum and bronchoalveolar lavage fluid in patients IPF(45, 46), and our measurements are consistent with the level reported by de Brouwer et. al.(45). Our work highlights the association between higher concentrations of elastokine and clinical prognosis. We observed a significant association between elastokine elevation and decreased FVC, the primary index used to evaluate therapeutic efficacy in IPF. We also observed a similar, though not statistically significant, association between elastokine concentration and reduced D\u003csub\u003eL\u003c/sub\u003eCO. These associations make intuitive sense as one would anticipate decreased lung function due to replacement of elastin, which confers tissue resilience, deformability, and elasticity by comparatively stiffer collagen and other ECM proteins. We previously demonstrated a decreased ratio of mature elastin relative to collage in patients with IPF(47), which supports the hypothesis that mature elastin is replaced by collagen in pulmonary fibrosis. Perhaps more importantly, in this study, we also observed an association between elastokine elevation and reduced three-year transplant-free survival. A correlation between elastokine concentration and GAP stage, a surrogate for mortality, further supported this finding.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOur study also offers a potential practical advantage as the method of measurement we utilized is technically easier (ELISA assay), more widely available, and allows for high throughput processing compared to previously reported techniques that are more time, technical, and resource intensive(45, 46). We also demonstrate that desmosine and isodesmosine are readily detectable in both healthy volunteers and patients with IPF. In addition, there was good correlation between isodesmosine and desmosine concentrations regardless of the source (serum vs urine). As both were similarly elevated in patients in IPF, this suggests that elastin remodeling is the inciting event leading to release of these amino acids into the circulation. Finally, we also demonstrate that urinary and serum elastokine concentrations are consistently and similarly elevated in IPF. This adds to previous data measuring increased concentrations of circulating desmosine and isodesmosine in plasma(45) and bronchoalveolar lavage(46) samples in patients with IPF.\u003c/p\u003e\n\u003cp\u003eWe acknowledge several limitations of the current study. First, we used a single-center retrospective cohort that comprised mostly Caucasian males. Although the sex distribution may be expected, we recognize that underrepresented minority patients are not included in our cohort and that our findings may not be generalizable to more ethnically diverse populations. Additionally, as the guideline-based definition of IPF evolved over the course of enrollment, some time-dependent discrepancies may have arisen in the clinical diagnosis of IPF. Some of our patients had combined pulmonary fibrosis and emphysema and/or WHO Group 3 pulmonary hypertension (\u0026lt;10% of our cohort), and it is unclear whether these co-morbid conditions contributed to the elevations in elastokine concentrations. We were unable to analyze associations between longitudinal changes in lung function, transplant-free survival, and elastokines due to an insufficient sample size. We were also unable to assess for longitudinal changes in elastokine concentrations as a function of anti-fibrotic medication for similar reasons. As expected, there was a significant difference in age between healthy volunteers and patients with IPF; however, we did not have age-matched controls to differentiate between age-related and disease-related elastokine concentrations. Others have reported disease-specific increases above those expected from aging alone with respect to desmosine concentrations(22). Some degree of caution in interpreting our analyses is warranted due to the possibility of a Type I error given the relatively small sample size and the restricted geography from which biospecimens were obtained. However, our sample size was adequate based on our power calculation. In addition, our data is consistent with and builds upon previously published data. We plan to validate our findings with larger cohorts and, potentially, a prospective trial, ideally using comparative biomarker analysis.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThere have been many promising biomarkers and clinical therapies, but for a variety of reasons, most do not achieve FDA approval(23). Emerging evidence suggests that elastokines are not simply a biomarker of lung tissue remodeling but might also contribute to lung pathology. In addition to desmosine, isodesmosine, other proteins are members of the elastokine family including\u0026nbsp;a-elastin,\u0026nbsp;k-elastin, and a group of peptides with a conserved VGVAPG domain(24, 25). Elastokines have been shown to induce signal transduction and cell activation via several receptors including\u0026nbsp;a\u003csub\u003ev\u003c/sub\u003eb\u003csub\u003e5\u003c/sub\u003e, galectrin-3, and integrins, but the majority of data suggests that the Elastin Receptor Complex (ERC) is probably the main receptor(25). This receptor is a heterotrimer composed of a peripheral subunit known as the Elastin Binding Protein, a protective protein/cathepsin A, and a membrane-associated protein called Neuraminidase-1. Elastokines have been shown to promote cell proliferation, invasion, survival, matrix metalloproteinase expression, angiogenesis, and fibroblast chemotaxis(26-32). Downstream signaling pathways of the ERC involve the MAP kinase family (ERK1/2) and pro-MMP-1 production(24). Preclinical administration of elastases is a well-established pre-clinical model of emphysema(33), however further research is needed into the mechanism(s) by which elastokines promote the development of emphysema and pulmonary fibrosis. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe progressive nature of IPF combined with the increasing world-wide incidence and prevalence of this disease(48), especially in the context of having only two partially effective therapies(3, 4), represents an unmet medical need. There are several potential novel therapeutics on the horizon, but many promising therapies have fallen short of demonstrating durable efficacy(23, 49). We propose that any additional insight into potential biomarkers and/or mechanistic understanding of this devastating disease will only help move the field of fibrosis research forward.\u0026nbsp;\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eElevated concentrations of circulating elastokines, a marker of matrix turnover, are associated with worse lung function and reduced three-year transplant-free survival in patients with IPF. These results need to be confirmed with a validation cohort and studies examining the mechanism of EDP-induced fibrosis are currently underway.\u003c/p\u003e"},{"header":"Study Design and Methods","content":"\u003cp\u003e\u003cstrong\u003eStudy sample: \u003c/strong\u003eThe institution\u0026rsquo;s ILD registry/biorepository was created with institutional approval in 2008 (STUDY00000503) and has been reviewed annually since its inception. The diagnosis of IPF was designated either according to the current professional guidelines or through multi-disciplinary discussion(34-38). Patients who expressed an interest in participating were consented at any time in the process of their disease and could donate biospecimens serially. For this analysis we used the first donation that was either the closest to when consent was obtained or when the diagnosis was first documented (often occurring at the same visit). Clinical outcomes (lung transplant or death) were then observed for a period of three years after initial sample collection. If the patient survived or did not receive a transplant during those three years, lung transplant-free survival was documented.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eUrinary and circulating elastokine measurement: \u003c/strong\u003eThe concentration of amino acids desmosine and isodesmosine was measured primarily in urine and serum via a commercially available enzyme-linked immunosorbent assay (ELISA) kit (mybiosource.com, Catalog # MBS702024 and MBS702214, respectively). Urine samples were available for the entire cohort (n=81 patients with IPF, n=24 healthy controls), and serum samples were available from a subset (n=24 patients with IPF, n=8 from healthy controls). We chose to use urine as the primary source because it is the least invasive and most widely available biospecimen in the repository. Samples were stored at -80\u0026deg; C until they were thawed for use. Duplicates for standards and each patient sample were used, and elastokine measurement was performed according to manufacturer instructions using replicates for each donor. The product literature states that for both assays, the intra-assay coefficient of variation is \u0026lt; 8% and the inter-assay precision has a coefficient of variation of \u0026lt; 10%. \u0026nbsp;Quatitative measurements were then obtained based on absorption at 450 nm with an iMark microplate reader (Bio-Rad). Results were then analyzed and graphed using GraphPad Prism (v10) or SAS (v9.4). \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePhysiologic Assessments: \u003c/strong\u003eSpirometry (forced vital capacity, FVC) and diffusing capacity for carbon monoxide (D\u003csub\u003eL\u003c/sub\u003eCO) were performed as part of standard clinical care, in accordance with current professional guidelines(39-41). Patients typically underwent lung function testing on the day of their clinical appointment; however, consent, enrollment, and sample donation may have occurred on a different day from their clinic appointment. In these cases, spirometry values that were obtained closest to the enrollment date were considered the baseline values for each participant.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdjudication of Death and Lung Transplantation: \u003c/strong\u003eDeath and lung transplantation status were adjudicated by the study personnel (investigators and study coordination staff). Time to censored event occurred for a period of 3 years following the initial date of sample donation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical Analysis:\u003c/strong\u003e Based on a prior study demonstrating the effect size of fold change in EDP concentration to be 10 units per 1 standard deviation(8) and confirmation of this effect size from our preliminary data, a patient sample size of 63 was deemed necessary to detect the same effect size at 80% power and a two-sided 0.05 significance level. Socio-demographic and clinical variables investigated include FVC, D\u003csub\u003eL\u003c/sub\u003eCO, smoking status, gender, ethnicity, race, age, presence of hypoxemia, and anti-fibrotic medication use. Linear and logistic regression modeling was utilized to determine associations between changes in urine EDP concentrations and lung function. Secondary analyses included the effect of anti-fibrotic medications on EDP concentration and assessment of associations between EDP concentrations at the time of diagnosis and clinical outcomes (time to respiratory-related hospitalization, transplant, or death). For the latter, we used time to event analysis to assess 3-year transplant-free survival. To create the comparator groups, we divided elastokine concentrations into tertiles. The GAP (Gender, Age, and lung Physiology) staging system was initially created(42) and subsequently validated(43) to assess 1, 2, and 3-year mortality in patients with IPF. We assessed EDP concentration as a function of GAP stage to provide additional support for the prognostic implications of elevated EDP concentrations. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIt is unknown if there is a relative difference in amino acid release between desmosine and isodesomine under conditions of elastinolysis. To assess the precision of urinary isodesmosine versus desmosine to detect a change in EDP concentrations, we selected a random sub-population and performed a correlation analysis based on urinary ELISA concentrations. It is also unclear if there are relative differences in EDP concentrations based on specimen source. To assess the accuracy of desmosine measurement between urinary and serum sources we used Bland-Altman analysis, using a different set of randomly selected patients.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAll statistical analysis was performed either with GraphPad Prism (v10, DJN) or SAS (v9.4, SL) software packages. Statistical significance was considered when p \u003cu\u003e\u0026lt;\u003c/u\u003e 0.05. Most figures were created using a combination of the above programs and BioRender (biorender.com)\u0026nbsp;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u003c/strong\u003e The authors would like to thank the current and former research coordinators and patients who donated specimens. We would also like to thank Drs. Patricia Rivera and Steve Georas for manuscript feedback.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions:\u0026nbsp;\u003c/strong\u003eDJN, RMK, and DH conceptualized the study. DJN was responsible for experimental design, data analysis, figure creation, and manuscript writing. TO and DJN performed ELISA analyses and DJN compiled results for statistical analysis. TJM, PJS, RMK, and DH provided project guidance, critical analysis of experimental results, and feedback on manuscript writing.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability:\u003c/strong\u003e The data that support the findings of this study are available from the corresponding author upon reasonable request. All patient-related information has been de-identified and each participant was assigned a unique identification upon consent.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests:\u0026nbsp;\u003c/strong\u003eThe authors do not have any competing interests to declare.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics Approval:\u0026nbsp;\u003c/strong\u003eThis study was performed in accordance with the Declaration of Helsinki. This human study was approved by University of Rochester Research Subjects Review Board - approval: STUDY00000503. All adult participants provided written informed consent to participate in this study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u0026nbsp;\u003c/strong\u003eDJN was supported by the URMC Multidisciplinary Training Program in Pulmonary Research (T32-HL066988, NHLBI), the URMC Department of Medicine Faculty Pilot Project Award, the NIH Loan Repayment Program (PTDX4691, NHLBI), and the CHEST Research Grant in Pulmonary Fibrosis (2023-2024). Statistical analysis was performed by SL and supported in part by the Department of Medicine Biostatistical Shared Resource and the University of Rochester School of Medicine and Dentistry.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eKaul B, Lee JS, Zhang N, Vittinghoff E, Sarmiento K, Collard HR, Whooley MA. Epidemiology of Idiopathic Pulmonary Fibrosis among U.S. Veterans, 2010-2019. \u003cem\u003eAnn Am Thorac Soc \u003c/em\u003e2022; 19: 196-203.\u003c/li\u003e\n\u003cli\u003eLey B, Collard HR, King TE, Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2011; 183: 431-440.\u003c/li\u003e\n\u003cli\u003eRicheldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. \u003cem\u003eThe New England journal of medicine \u003c/em\u003e2014; 370: 2071-2082.\u003c/li\u003e\n\u003cli\u003eKing TE, Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. \u003cem\u003eThe New England journal of medicine \u003c/em\u003e2014; 370: 2083-2092.\u003c/li\u003e\n\u003cli\u003eValapour M, Lehr CJ, Skeans MA, Smith JM, Carrico R, Uccellini K, Lehman R, Robinson A, Israni AK, Snyder JJ, Kasiske BL. OPTN/SRTR 2016 Annual Data Report: Lung. \u003cem\u003eAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons \u003c/em\u003e2018; 18 Suppl 1: 363-433.\u003c/li\u003e\n\u003cli\u003eThabut G, Mal H. Outcomes after lung transplantation. \u003cem\u003eJ Thorac Dis \u003c/em\u003e2017; 9: 2684-2691.\u003c/li\u003e\n\u003cli\u003eKristensen JH, Karsdal MA, Sand JM, Willumsen N, Diefenbach C, Svensson B, Hagglund P, Oersnes-Leeming DJ. Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling. \u003cem\u003eBMC pulmonary medicine \u003c/em\u003e2015; 15: 53.\u003c/li\u003e\n\u003cli\u003eStarcher BC. Elastin and the lung. \u003cem\u003eThorax \u003c/em\u003e1986; 41: 577-585.\u003c/li\u003e\n\u003cli\u003eMithieux SM, Weiss AS. Tandem integration of multiple ILV5 copies and elevated transcription in polyploid yeast. \u003cem\u003eYeast \u003c/em\u003e1995; 11: 311-316.\u003c/li\u003e\n\u003cli\u003eShapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. \u003cem\u003eJ Clin Invest \u003c/em\u003e1991; 87: 1828-1834.\u003c/li\u003e\n\u003cli\u003eBoisvert F-M, Ahmad Y, Gierliński M, Charri\u0026egrave;re F, Lamont D, Scott M, Barton G, Lamond AI. A quantitative spatial proteomics analysis of proteome turnover in human cells. \u003cem\u003eMolecular \u0026amp; Cellular Proteomics \u003c/em\u003e2012; 11.\u003c/li\u003e\n\u003cli\u003eCocciolone AJ, Hawes JZ, Staiculescu MC, Johnson EO, Murshed M, Wagenseil JE. Elastin, arterial mechanics, and cardiovascular disease. \u003cem\u003eAm J Physiol Heart Circ Physiol \u003c/em\u003e2018; 315: H189-h205.\u003c/li\u003e\n\u003cli\u003eZhang MC, Giro M, Quaglino D, Jr., Davidson JM. Transforming growth factor-beta reverses a posttranscriptional defect in elastin synthesis in a cutis laxa skin fibroblast strain. \u003cem\u003eJ Clin Invest \u003c/em\u003e1995; 95: 986-994.\u003c/li\u003e\n\u003cli\u003eKatsuta Y, Ogura Y, Iriyama S, Goetinck PF, Klement JF, Uitto J, Amano S. Fibulin-5 accelerates elastic fibre assembly in human skin fibroblasts. \u003cem\u003eExp Dermatol \u003c/em\u003e2008; 17: 837-842.\u003c/li\u003e\n\u003cli\u003eHuang JT, Bolton CE, Miller BE, Tal-Singer R, Rabinovich RA, Palmer CN, Thomson NC, MacNee W. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. \u003cem\u003eThe European respiratory journal \u003c/em\u003e2016; 48: 1215-1218.\u003c/li\u003e\n\u003cli\u003eHuang JT, Kuzmanova E, Dicker AJ, Keir HR, Finch S, Aliberti S, Fardon TC, Chalmers JD. Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2020; 202: 897-899.\u003c/li\u003e\n\u003cli\u003eRabinovich RA, Miller BE, Wrobel K, Ranjit K, Williams MC, Drost E, Edwards LD, Lomas DA, Rennard SI, Agust\u0026iacute; A, Tal-Singer R, Vestbo J, Wouters EF, John M, van Beek EJ, Murchison JT, Bolton CE, MacNee W, Huang JT. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. \u003cem\u003eThe European respiratory journal \u003c/em\u003e2016; 47: 1365-1373.\u003c/li\u003e\n\u003cli\u003eFregonese L, Ferrari F, Fumagalli M, Luisetti M, Stolk J, Iadarola P. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antritrypsin deficiency-related COPD. \u003cem\u003eCopd \u003c/em\u003e2011; 8: 329-333.\u003c/li\u003e\n\u003cli\u003eTurino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2011; 184: 637-641.\u003c/li\u003e\n\u003cli\u003eKim YM, Haghighat L, Spiekerkoetter E, Sawada H, Alvira CM, Wang L, Acharya S, Rodriguez-Colon G, Orton A, Zhao M, Rabinovitch M. Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. \u003cem\u003eThe American journal of pathology \u003c/em\u003e2011; 179: 1560-1572.\u003c/li\u003e\n\u003cli\u003eShek N, Choy AM, Lang CC, Miller BE, Tal-Singer R, Bolton CE, Thomson NC, Chalmers JD, Bown MJ, Newby DE, Khan F, Huang JTJ. Accelerated elastin degradation by age-disease interaction: a common feature in age-related diseases. \u003cem\u003eNPJ Aging \u003c/em\u003e2024; 10: 15.\u003c/li\u003e\n\u003cli\u003eHuang JTJ, Bolton CE, Miller BE, Tal-Singer R, Rabinovich RA, Palmer CNA, Thomson NC, MacNee W. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. \u003cem\u003eEuropean Respiratory Journal \u003c/em\u003e2016; 48: 1215-1218.\u003c/li\u003e\n\u003cli\u003eRackow AR, Nagel DJ, McCarthy C, Judge J, Lacy S, Freeberg MAT, Thatcher TH, Kottmann RM, Sime PJ. The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops. \u003cem\u003eThe European respiratory journal \u003c/em\u003e2020; 56.\u003c/li\u003e\n\u003cli\u003eDuca L, Blanchevoye C, Cantarelli B, Ghoneim C, Dedieu S, Delacoux F, Hornebeck W, Hinek A, Martiny L, Debelle L. The elastin receptor complex transduces signals through the catalytic activity of its Neu-1 subunit. \u003cem\u003eThe Journal of biological chemistry \u003c/em\u003e2007; 282: 12484-12491.\u003c/li\u003e\n\u003cli\u003eScandolera A, Odoul L, Salesse S, Guillot A, Blaise S, Kawecki C, Maurice P, El Btaouri H, Romier-Crouzet B, Martiny L, Debelle L, Duca L. The Elastin Receptor Complex: A Unique Matricellular Receptor with High Anti-tumoral Potential. \u003cem\u003eFront Pharmacol \u003c/em\u003e2016; 7: 32.\u003c/li\u003e\n\u003cli\u003eBrassart B, Randoux A, Hornebeck W, Emonard H. Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. \u003cem\u003eClinical \u0026amp; experimental metastasis \u003c/em\u003e1998; 16: 489-500.\u003c/li\u003e\n\u003cli\u003eCoquerel B, Poyer F, Torossian F, Dulong V, Bellon G, Dubus I, Reber A, Vannier JP. Elastin-derived peptides: matrikines critical for glioblastoma cell aggressiveness in a 3-D system. \u003cem\u003eGlia \u003c/em\u003e2009; 57: 1716-1726.\u003c/li\u003e\n\u003cli\u003eDonet M, Brassart-Pasco S, Salesse S, Maquart FX, Brassart B. Elastin peptides regulate HT-1080 fibrosarcoma cell migration and invasion through an Hsp90-dependent mechanism. \u003cem\u003eBr J Cancer \u003c/em\u003e2014; 111: 139-148.\u003c/li\u003e\n\u003cli\u003eDuca L, Lambert E, Debret R, Rothhut B, Blanchevoye C, Delacoux F, Hornebeck W, Martiny L, Debelle L. Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts. \u003cem\u003eMolecular pharmacology \u003c/em\u003e2005; 67: 1315-1324.\u003c/li\u003e\n\u003cli\u003eNtayi C, Labrousse AL, Debret R, Birembaut P, Bellon G, Antonicelli F, Hornebeck W, Bernard P. Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma cell invasion through elastin-binding protein. \u003cem\u003eJ Invest Dermatol \u003c/em\u003e2004; 122: 256-265.\u003c/li\u003e\n\u003cli\u003eSenior RM, Griffin GL, Mecham RP, Wrenn DS, Prasad KU, Urry DW. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. \u003cem\u003eThe Journal of cell biology \u003c/em\u003e1984; 99: 870-874.\u003c/li\u003e\n\u003cli\u003eToupance S, Brassart B, Rabenoelina F, Ghoneim C, Vallar L, Polette M, Debelle L, Birembaut P. Elastin-derived peptides increase invasive capacities of lung cancer cells by post-transcriptional regulation of MMP-2 and uPA. \u003cem\u003eClinical \u0026amp; experimental metastasis \u003c/em\u003e2012; 29: 511-522.\u003c/li\u003e\n\u003cli\u003eKuhn C, Senior RM. The role of elastases in the development of emphysema. \u003cem\u003eLung \u003c/em\u003e1978; 155: 185-197.\u003c/li\u003e\n\u003cli\u003eAmerican Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2000; 161: 646-664.\u003c/li\u003e\n\u003cli\u003eErratum: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2015; 192: 644.\u003c/li\u003e\n\u003cli\u003eRaghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Jr., Kondoh Y, Myers J, M\u0026uuml;ller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Sch\u0026uuml;nemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2011; 183: 788-824.\u003c/li\u003e\n\u003cli\u003eRaghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2018; 198: e44-e68.\u003c/li\u003e\n\u003cli\u003eRaghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2022; 205: e18-e47.\u003c/li\u003e\n\u003cli\u003eGraham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, MacIntyre NR, Thompson BR, Wanger J. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. \u003cem\u003eThe European respiratory journal \u003c/em\u003e2017; 49.\u003c/li\u003e\n\u003cli\u003eGraham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. \u003cem\u003eAm J Respir Crit Care Med \u003c/em\u003e2019; 200: e70-e88.\u003c/li\u003e\n\u003cli\u003eMiller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. \u003cem\u003eThe European respiratory journal \u003c/em\u003e2005; 26: 319-338.\u003c/li\u003e\n\u003cli\u003eLey B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Jr., Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. \u003cem\u003eAnn Intern Med \u003c/em\u003e2012; 156: 684-691.\u003c/li\u003e\n\u003cli\u003eKim ES, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM. Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. \u003cem\u003eChest \u003c/em\u003e2015; 147: 430-437.\u003c/li\u003e\n\u003cli\u003eKarimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. \u003cem\u003eThe New England journal of medicine \u003c/em\u003e2015; 372: 1189-1191.\u003c/li\u003e\n\u003cli\u003ede Brouwer B, Drent M, van den Ouweland JMW, Wijnen PA, van Moorsel CHM, Bekers O, Grutters JC, White ES, Janssen R. Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis. \u003cem\u003eRespiratory research \u003c/em\u003e2018; 19: 45.\u003c/li\u003e\n\u003cli\u003eSato T, Kajikuri T, Saito Y, Chikuma M, Nagai S. Determination of desmosine in bronchoalveolar lavage fluids by time-resolved fluoroimmunoassay. \u003cem\u003eClinica chimica acta; international journal of clinical chemistry \u003c/em\u003e2008; 387: 113-119.\u003c/li\u003e\n\u003cli\u003eKottmann RM, Sharp J, Owens K, Salzman P, Xiao GQ, Phipps RP, Sime PJ, Brown EB, Perry SW. Second harmonic generation microscopy reveals altered collagen microstructure in usual interstitial pneumonia versus healthy lung. \u003cem\u003eRespiratory research \u003c/em\u003e2015; 16: 61.\u003c/li\u003e\n\u003cli\u003eKing TE, Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. \u003cem\u003eLancet (London, England) \u003c/em\u003e2011; 378: 1949-1961.\u003c/li\u003e\n\u003cli\u003eFuster-Mart\u0026iacute;nez I, Calatayud S. The current landscape of antifibrotic therapy across different organs: A systematic approach. \u003cem\u003ePharmacol Res \u003c/em\u003e2024; 205: 107245. \u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Table","content":"\u003cp\u003e\u003cstrong\u003eTable 1:\u0026nbsp;\u003c/strong\u003eBaseline patient characteristics.\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"684\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHealthy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eIPF\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (Yrs)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003eN=24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003eN=81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eMedian (IQR)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e40.0 (29.0 : 63.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e71.0 (66.0 : 79.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGender\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e0.006\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e9 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e58 (71.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e15 (62.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e23 (28.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRace\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e0.21\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; White\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e22 (91.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e79 (97.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; Non-white\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e2 (8.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e2 (2.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eEver smoker\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e0.021\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e14 (58.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e25 (30.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e10 (41.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e56 (69.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBMI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e0.005\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eMedian (IQR)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e24.4 (23.3 : 28.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e28.0 (25.7 : 32.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFVC (% predicted)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eMedian (IQR)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e99.0 (91.0 : 108.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e72.0 (64.0 : 84.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD\u003csub\u003eL\u003c/sub\u003eCO (% predicted)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003eN=2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003eN=80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eMedian (IQR)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e96.5 (84.0 : 109.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e46.0 (37.0 : 54.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDesmosine (ng/mL)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eMedian (IQR)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0.3 (0.2 : 0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e1.4 (0.8 : 2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOxygen needs\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e23 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e38 (46.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e43 (53.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAnti-fibrotic use\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e44 (54.32%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e37 (45.68%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDeath\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e28 (34.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e53 (65.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTransplant\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e72 (87.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 174px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 168px;\"\u003e\n \u003cp\u003e10 (12.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 144px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eData comparing healthy volunteers and patients with IPF are presented as No. (%) with median and interquartile ranges for relevant parameters. Among those with IPF, patients were more likely to be male (71.6% vs 28.4%, p = 0.0001), Caucasian (97.5% vs 2.5%, p \u0026lt;0.0001), and have ever smoked (69.1% vs 30.9%, p = 0.0006).\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"pulmonary fibrosis, elastokines, elastin degradation products, extracellular matrix remodeling, and transplant-free survival","lastPublishedDoi":"10.21203/rs.3.rs-7881084/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7881084/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eDuring the development of idiopathic pulmonary fibrosis (IPF), elastin is broken down and replaced with a stiffer substrate which interferes with normal breathing. This remodeling releases elastin degradation products (EDPs), or elastokines, which can then be measured. We examined the association between elastokine concentrations and disease severity to determine if EDP concentrations are associated with clinically relevant markers in IPF.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eConcentrations of elastokines were measured via enzyme linked immunosorbent assay (ELISA). Samples were obtained from a single institution\u0026rsquo;s Interstitial Lung Disease (ILD) registry/biorepository (n\u0026thinsp;=\u0026thinsp;81 with IPF and 24 healthy volunteers). We used linear and logistic regression modeling to assess the association between EDP concentrations at the time of diagnosis, lung function, and clinical outcomes.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003ePatients with IPF were older, more likely to be male, had ever smoked, and had worse lung function compared to healthy volunteers (p value\u0026thinsp;\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e\u0026le;\u003c/span\u003e\u0026thinsp;0.02 for all parameters). Patients with IPF had higher concentrations of elasotkines (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), and the highest elastokine concentrations were associated with reduced forced vital capacity (FVC, p\u0026thinsp;=\u0026thinsp;0.026), and decreased three-year transplant-free survival (p\u0026thinsp;=\u0026thinsp;0.0005). These findings suggest that elastokines are biomarkers of matrix turnover and are associated with relevant clinical outcomes in patients with IPF.\u003c/p\u003e","manuscriptTitle":"Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary Fibrosis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-12-30 10:00:03","doi":"10.21203/rs.3.rs-7881084/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-02-09T10:52:30+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-01-19T22:56:16+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"249790731242846207586699899654986740964","date":"2026-01-08T00:09:43+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"188887819081949025193162154875483333135","date":"2026-01-02T16:08:17+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-12-25T20:31:40+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"179664543607378875256608038532972099073","date":"2025-12-25T19:11:59+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-12-25T17:38:44+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-10-30T15:05:27+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-10-17T06:43:03+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-10-17T06:39:56+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2025-10-16T22:06:20+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2f585616-223f-4094-b6dd-afab9ebc077f","owner":[],"postedDate":"December 30th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":60278318,"name":"Health sciences/Biomarkers"},{"id":60278319,"name":"Health sciences/Diseases"},{"id":60278320,"name":"Health sciences/Medical research"}],"tags":[],"updatedAt":"2026-04-30T05:40:03+00:00","versionOfRecord":[],"versionCreatedAt":"2025-12-30 10:00:03","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7881084","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7881084","identity":"rs-7881084","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}